P128 Transplant patients with HLA allele antibodies need donors typed at that level

We are disadvantaging pre and post transplant patients who have potential HLA allele donor specific antibodies (DSAs), when deceased donors are not typed an intermediate or high resolution. How can we estimate the antibody mediated rejection risk (AMR), when we can’t tell if an allele antibody is a DSA? With RT-PCR, SSP and rSSO, we have the ability to type donors in 3–6 h at intermediate to near allele level, why isn’t this level required, it...